Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma

Yu Ri Kim, Soo Jeong Kim, June Won Cheong, Haerim Chung, Ji Eun Jang, Yundeok Kim, Woo Ick Yang, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Because there are few studies regarding the clinical impact of circulating EBVDNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBVDNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBVDNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.

Original languageEnglish
Pages (from-to)92312-92323
Number of pages12
JournalOncotarget
Volume8
Issue number54
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Peripheral T-Cell Lymphoma
Human Herpesvirus 4
Disease-Free Survival
DNA
Survival
Albumins
Oxidoreductases
Milk

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Yu Ri ; Kim, Soo Jeong ; Cheong, June Won ; Chung, Haerim ; Jang, Ji Eun ; Kim, Yundeok ; Yang, Woo Ick ; Min, Yoo Hong ; Kim, Jin Seok. / Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 54. pp. 92312-92323.
@article{ca381a94c767446e8846704ef4d697a8,
title = "Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma",
abstract = "Because there are few studies regarding the clinical impact of circulating EBVDNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBVDNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7{\%}) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0{\%} and 18.0{\%}. Univariable analysis showed that positive EBVDNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.",
author = "Kim, {Yu Ri} and Kim, {Soo Jeong} and Cheong, {June Won} and Haerim Chung and Jang, {Ji Eun} and Yundeok Kim and Yang, {Woo Ick} and Min, {Yoo Hong} and Kim, {Jin Seok}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21251",
language = "English",
volume = "8",
pages = "92312--92323",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "54",

}

Kim, YR, Kim, SJ, Cheong, JW, Chung, H, Jang, JE, Kim, Y, Yang, WI, Min, YH & Kim, JS 2017, 'Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma', Oncotarget, vol. 8, no. 54, pp. 92312-92323. https://doi.org/10.18632/oncotarget.21251

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. / Kim, Yu Ri; Kim, Soo Jeong; Cheong, June Won; Chung, Haerim; Jang, Ji Eun; Kim, Yundeok; Yang, Woo Ick; Min, Yoo Hong; Kim, Jin Seok.

In: Oncotarget, Vol. 8, No. 54, 01.01.2017, p. 92312-92323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma

AU - Kim, Yu Ri

AU - Kim, Soo Jeong

AU - Cheong, June Won

AU - Chung, Haerim

AU - Jang, Ji Eun

AU - Kim, Yundeok

AU - Yang, Woo Ick

AU - Min, Yoo Hong

AU - Kim, Jin Seok

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Because there are few studies regarding the clinical impact of circulating EBVDNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBVDNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBVDNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.

AB - Because there are few studies regarding the clinical impact of circulating EBVDNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBVDNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBVDNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.

UR - http://www.scopus.com/inward/record.url?scp=85032655038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032655038&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21251

DO - 10.18632/oncotarget.21251

M3 - Article

AN - SCOPUS:85032655038

VL - 8

SP - 92312

EP - 92323

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 54

ER -